Eli Lilly reported additional late-stage results for retatrutide, advancing its “triple-G” obesity program toward an FDA biologics license application. New Phase 3 data in trials spanning obesity with type 2 diabetes and cardiovascular complications showed continued weight-loss performance, while clarifying the cardiovascular risk question. Separately, a companion report noted that while retatrutide met weight-loss endpoints, it left uncertainty on whether it reduces cardiovascular events compared with established obesity therapies. Lilly said the new findings position the company for a filing path early next year. For competitors and payers, the key implication is that dosing and outcomes beyond weight—especially heart outcomes—remain central to differentiating incretin competitors as regulatory reviews approach.